HCSG vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HCSG exhibits exceptional financial health, highlighted by a strong Piotroski F-Score of 8/9 and a near-zero Debt/Equity ratio of 0.03. While the current price of $19.49 is a premium to the Graham Number ($11.56), it remains well below the growth-based intrinsic value of $23.90. Explosive year-over-year earnings growth (172.4%) and a low Price-to-Sales ratio (0.75) suggest significant value creation despite thin profit margins. The primary headwinds are bearish insider sentiment and a negative short-term technical trend.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HCSG vs LLY: Head-to-Head Comparison
This page compares Healthcare Services Group, Inc. (HCSG) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.